Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
|
In millions, except per share items | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 |
| 10-K | 10-K | 10-K | 10-K/A | 10-K | 10-K | 10-K | 10-K |
Revenues: |
Radiology | 350.8 | 339.6 | 343.5 | 371.0 | 389.1 | | | |
Oncology | 107.2 | 100.0 | 92.9 | 77.9 | | | | |
Other radiology | 26.6 | 27.4 | 29.4 | 38.7 | | | | |
Imaging | | | | | | 418.4 | 434.4 | 469.1 |
Other | 21.0 | 6.1 | | | 83.2 | 75.2 | 44.4 | 36.5 |
Total revenues | 505.5 | 473.1 | 436.4 | 448.8 | 472.3 | 493.7 | 478.9 | 505.5 |
Revenue growth [+] | 6.9% | 8.4% | -2.8% | -5.0% | -4.3% | 3.1% | -5.3% | 2.0% |
Radiology | 3.3% | -1.1% | -7.4% | -4.7% | | | | |
Oncology | 7.3% | 7.6% | 19.3% | | | | | |
Other radiology | -3.0% | -7.0% | -24.0% | | | | | |
Imaging | | | | | | -3.7% | -7.4% | -0.5% |
Radiation Oncology | | | | | 10.6% | 69.2% | 21.9% | 48.0% |
Cost of goods sold | 285.7 | 269.1 | 237.4 | 239.4 | 253.2 | 279.8 | 264.7 | 270.4 |
Gross profit | 219.8 | 204.0 | 199.0 | 209.4 | 219.0 | 213.9 | 214.1 | 235.1 |
Gross margin | 43.5% | 43.1% | 45.6% | 46.7% | 46.4% | 43.3% | 44.7% | 46.5% |
Selling, general and administrative | 96.7 | 88.5 | 79.9 | 80.2 | 76.0 | 77.1 | 67.1 | 67.6 |
Equity in earnings | 1.3 | 3.4 | 4.7 | -5.6 | 4.7 | 3.5 | 4.3 | 3.8 |
Other operating expenses | 57.9 | 38.7 | 63.9 | 162.9 | 102.1 | 113.9 | 110.1 | 140.4 |
EBITDA [+] | 132.1 | 138.1 | 122.7 | 38.0 | 140.8 | 132.8 | 146.0 | 136.9 |
EBITDA growth | -4.4% | 12.6% | 222.8% | -73.0% | 6.0% | -9.1% | 6.6% | -20.1% |
EBITDA margin | 26.1% | 29.2% | 28.1% | 8.5% | 29.8% | 26.9% | 30.5% | 27.1% |
Depreciation | 55.0 | 48.6 | 55.0 | 77.3 | 79.3 | 90.0 | 92.3 | 94.9 |
EBITA | 77.1 | 89.5 | 67.7 | -39.3 | 61.5 | 42.8 | 53.7 | 42.0 |
EBITA margin | 15.3% | 18.9% | 15.5% | -8.8% | 13.0% | 8.7% | 11.2% | 8.3% |
Amortization of intangibles | 10.6 | 9.3 | 7.9 | | 15.9 | 16.4 | 12.4 | 11.0 |
EBIT [+] | 66.6 | 80.2 | 59.9 | -39.3 | 45.6 | 26.4 | 41.3 | 31.0 |
EBIT growth | -17.0% | 34.0% | -252.4% | -186.2% | 73.0% | -36.1% | 33.0% | -58.6% |
EBIT margin | 13.2% | 17.0% | 13.7% | -8.8% | 9.7% | 5.3% | 8.6% | 6.1% |
Non-recurring items [+] | 6.4 | 11.5 | 5.2 | 15.2 | 1.0 | 171.2 | 44.5 | 0.9 |
Asset impairment | 0.6 | 6.8 | 0.3 | 13.0 | | 167.8 | 42.1 | |
Interest expense, net [+] | 34.5 | 26.2 | 24.7 | | 54.1 | 49.8 | 51.2 | 45.8 |
Interest expense | 34.5 | 26.2 | 24.7 | | 54.1 | 49.8 | 51.2 | 45.9 |
Interest income | | | | | | | | 0.1 |
Other income (expense), net [+] | -6.6 | -12.3 | -1.8 | 28.0 | -3.0 | -2.2 | 0.6 | 15.6 |
Gain (loss) on debt retirement | | | | -26.0 | | | | -14.6 |
Other | -6.6 | -12.3 | -1.8 | 1.9 | -3.0 | -2.2 | 0.6 | 1.2 |
Pre-tax income | 19.0 | 30.3 | 28.2 | -26.5 | -12.5 | -196.9 | -53.9 | 0.0 |
Income taxes | 2.9 | 6.5 | 7.3 | -12.4 | -6.7 | -38.2 | -20.8 | 0.3 |
Tax rate | 15.0% | 21.6% | 26.0% | 46.8% | 53.5% | 19.4% | 38.6% | 1400.0% |
Minority interest | 17.0 | 20.4 | 14.9 | 13.0 | 10.8 | 5.0 | 3.9 | 3.1 |
Net income | 0.5 | 6.7 | 10.6 | -21.5 | -11.9 | -160.1 | -32.7 | 0.5 |
Net margin | 0.1% | 1.4% | 2.4% | -4.8% | -2.5% | -32.4% | -6.8% | 0.1% |
|
Basic EPS [+] | $0.05 | $0.63 | $1.00 | ($2.02) | ($1.12) | ($15.07) | ($3.09) | $0.01 |
Growth | -92.8% | -36.9% | -149.3% | 79.8% | -92.5% | 387.1% | -33372.7% | |
Diluted EPS [+] | $0.04 | $0.62 | $0.98 | ($2.02) | ($1.12) | ($15.07) | ($3.09) | $0.01 |
Growth | -92.8% | -36.6% | -148.5% | 79.8% | -92.5% | 387.1% | -33640.9% | |
|
Shares outstanding (basic) [+] | 10.9 | 10.7 | 10.7 | 10.6 | 10.6 | 10.6 | 10.6 | 51.7 |
Growth | 1.2% | 0.7% | 0.3% | 0.1% | 0.0% | 0.7% | -79.6% | 0.9% |
Shares outstanding (diluted) [+] | 11.0 | 10.8 | 10.8 | 10.6 | 10.6 | 10.6 | 10.6 | 52.2 |
Growth | 1.0% | 0.1% | 1.9% | 0.1% | 0.0% | 0.7% | -79.8% | 0.0% |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|